Format

Send to

Choose Destination
J Alzheimers Dis. 2019;68(1):33-38. doi: 10.3233/JAD-181043.

Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer's Disease.

Author information

1
Department of Internal Medicine, Gerontology & Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
2
Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
3
Department of Neurobiology and Anatomy, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Abstract

Currently there is no cure or effective disease-modifying therapy for Alzheimer's disease (AD), the most common form of dementia that is becoming a global threat to public health. It is important to develop novel therapeutic strategies targeting AD pathophysiology particularly synaptic failure and cognitive impairments. Recent studies revealed several molecular signaling pathways potentially linked to brain pathology and synaptic failure in AD, including AMP-activated protein kinase (AMPK), a master kinase that plays a central role in the maintenance of cellular energy homeostasis. Particularly, hyperactive AMPK via phosphorylation has been linked to AD-associated synaptic plasticity impairments, indicating suppression of AMPK activity might be beneficial for cognitive deficiency in AD. In this review, we will discuss how targeting dysregulation of AMPK signaling could be a feasible therapeutic approach for AD.

KEYWORDS:

AMPK; Alzheimer’s disease; protein synthesis; signaling transduction; synaptic plasticity

Supplemental Content

Full text links

Icon for IOS Press Icon for PubMed Central
Loading ...
Support Center